Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.
Haematologica|December 7, 2023
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive diseaseSabine Kayser, Chiara Sartor, Fabio Giglio, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Leukemia & Lymphoma|April 5, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapyTheodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek, et al.
Leukemia & Lymphoma|February 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for <i>BCR-ABL</i> B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantationJohn Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur, et al.
Haematologica|June 11, 2026
Evolution to complex karyotype disease in mono-allelic <i>TP53</i>-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort studyPriyanka Fernandes, Sergiu Pasca, Tania Jain, et al.
Blood|May 12, 2017
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysisCatherine C Smith, Amy Paguirigan, Grace R Jeschke, et al.
Leukemia & Lymphoma|February 6, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary diseaseKhaled Sanber, Kevin Ye, Hua-Ling Tsai, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
British Journal of Haematology|May 19, 2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemiasAmer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, et al.
Blood|January 21, 2012
A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemiaJonathan M Gerber, B Douglas Smith, Brownhilda Ngwang, et al.
Leukemia Research|December 8, 2009
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemiaJudith E Karp, Amanda Blackford, B Douglas Smith, et al.
Haematologica|December 7, 2023
Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive diseaseSabine Kayser, Chiara Sartor, Fabio Giglio, et al.
Pageof 14